Anal carcinoma

Wayne A I Frederick, Neil Bhayani, Debra Ford, Gary Yang, Charles Thomas

Research output: Contribution to journalArticle

Abstract

Anal carcinoma accounts for less than 2% of all gastrointestinal malignancies. The incidence of anal cancer is increasing and may be associated with an increase in anal receptive intercourse or higher number of sexual partners. Such behaviors have also increased the risk of infection with both HIV and human papilloma virus (HPV). HPV appears to induce dysplasia in the anal mucosa, which is readily detectable and treatable. The strong association of HPV has even spurred research into primary prevention in high-risk patients. Models suggest that screening in the highest risk patients would not only confer a survival benefit but also be cost effective. While the overall prognosis is only a 55% survival at 5 years, survival for localized disease remains near 80%. Traditional staging by cross-sectional imaging may be giving way to endorectal ultrasound and sentinel node biopsy. The standard of care for anal canal carcinoma is now combined modality therapy (CMT) with chemoradiation therapy obtaining excellent oncologic results as well as organ preservation. Advances in intensity modulated radiation therapy (IMRT) and brachytherapy have significantly decreased toxicity. Surgery improves survival in patients with persistent or residual disease Within the next decade, anal cancer may emerge as a preventable form of cancer.

Original languageEnglish (US)
Pages (from-to)142-150
Number of pages9
JournalCurrent Cancer Therapy Reviews
Volume5
Issue number2
DOIs
StatePublished - 2009

Fingerprint

Papillomaviridae
Anus Neoplasms
Carcinoma
Survival
Organ Preservation
Combined Modality Therapy
Sexual Partners
Brachytherapy
Primary Prevention
Standard of Care
Neoplasms
Mucous Membrane
Radiotherapy
HIV
Biopsy
Costs and Cost Analysis
Incidence
Infection
Research

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Molecular Medicine

Cite this

Frederick, W. A. I., Bhayani, N., Ford, D., Yang, G., & Thomas, C. (2009). Anal carcinoma. Current Cancer Therapy Reviews, 5(2), 142-150. https://doi.org/10.2174/157339409788166751

Anal carcinoma. / Frederick, Wayne A I; Bhayani, Neil; Ford, Debra; Yang, Gary; Thomas, Charles.

In: Current Cancer Therapy Reviews, Vol. 5, No. 2, 2009, p. 142-150.

Research output: Contribution to journalArticle

Frederick, WAI, Bhayani, N, Ford, D, Yang, G & Thomas, C 2009, 'Anal carcinoma', Current Cancer Therapy Reviews, vol. 5, no. 2, pp. 142-150. https://doi.org/10.2174/157339409788166751
Frederick WAI, Bhayani N, Ford D, Yang G, Thomas C. Anal carcinoma. Current Cancer Therapy Reviews. 2009;5(2):142-150. https://doi.org/10.2174/157339409788166751
Frederick, Wayne A I ; Bhayani, Neil ; Ford, Debra ; Yang, Gary ; Thomas, Charles. / Anal carcinoma. In: Current Cancer Therapy Reviews. 2009 ; Vol. 5, No. 2. pp. 142-150.
@article{68c388e0a34448feb2df123d8cf055b3,
title = "Anal carcinoma",
abstract = "Anal carcinoma accounts for less than 2{\%} of all gastrointestinal malignancies. The incidence of anal cancer is increasing and may be associated with an increase in anal receptive intercourse or higher number of sexual partners. Such behaviors have also increased the risk of infection with both HIV and human papilloma virus (HPV). HPV appears to induce dysplasia in the anal mucosa, which is readily detectable and treatable. The strong association of HPV has even spurred research into primary prevention in high-risk patients. Models suggest that screening in the highest risk patients would not only confer a survival benefit but also be cost effective. While the overall prognosis is only a 55{\%} survival at 5 years, survival for localized disease remains near 80{\%}. Traditional staging by cross-sectional imaging may be giving way to endorectal ultrasound and sentinel node biopsy. The standard of care for anal canal carcinoma is now combined modality therapy (CMT) with chemoradiation therapy obtaining excellent oncologic results as well as organ preservation. Advances in intensity modulated radiation therapy (IMRT) and brachytherapy have significantly decreased toxicity. Surgery improves survival in patients with persistent or residual disease Within the next decade, anal cancer may emerge as a preventable form of cancer.",
author = "Frederick, {Wayne A I} and Neil Bhayani and Debra Ford and Gary Yang and Charles Thomas",
year = "2009",
doi = "10.2174/157339409788166751",
language = "English (US)",
volume = "5",
pages = "142--150",
journal = "Current Cancer Therapy Reviews",
issn = "1573-3947",
publisher = "Bentham Science Publishers B.V.",
number = "2",

}

TY - JOUR

T1 - Anal carcinoma

AU - Frederick, Wayne A I

AU - Bhayani, Neil

AU - Ford, Debra

AU - Yang, Gary

AU - Thomas, Charles

PY - 2009

Y1 - 2009

N2 - Anal carcinoma accounts for less than 2% of all gastrointestinal malignancies. The incidence of anal cancer is increasing and may be associated with an increase in anal receptive intercourse or higher number of sexual partners. Such behaviors have also increased the risk of infection with both HIV and human papilloma virus (HPV). HPV appears to induce dysplasia in the anal mucosa, which is readily detectable and treatable. The strong association of HPV has even spurred research into primary prevention in high-risk patients. Models suggest that screening in the highest risk patients would not only confer a survival benefit but also be cost effective. While the overall prognosis is only a 55% survival at 5 years, survival for localized disease remains near 80%. Traditional staging by cross-sectional imaging may be giving way to endorectal ultrasound and sentinel node biopsy. The standard of care for anal canal carcinoma is now combined modality therapy (CMT) with chemoradiation therapy obtaining excellent oncologic results as well as organ preservation. Advances in intensity modulated radiation therapy (IMRT) and brachytherapy have significantly decreased toxicity. Surgery improves survival in patients with persistent or residual disease Within the next decade, anal cancer may emerge as a preventable form of cancer.

AB - Anal carcinoma accounts for less than 2% of all gastrointestinal malignancies. The incidence of anal cancer is increasing and may be associated with an increase in anal receptive intercourse or higher number of sexual partners. Such behaviors have also increased the risk of infection with both HIV and human papilloma virus (HPV). HPV appears to induce dysplasia in the anal mucosa, which is readily detectable and treatable. The strong association of HPV has even spurred research into primary prevention in high-risk patients. Models suggest that screening in the highest risk patients would not only confer a survival benefit but also be cost effective. While the overall prognosis is only a 55% survival at 5 years, survival for localized disease remains near 80%. Traditional staging by cross-sectional imaging may be giving way to endorectal ultrasound and sentinel node biopsy. The standard of care for anal canal carcinoma is now combined modality therapy (CMT) with chemoradiation therapy obtaining excellent oncologic results as well as organ preservation. Advances in intensity modulated radiation therapy (IMRT) and brachytherapy have significantly decreased toxicity. Surgery improves survival in patients with persistent or residual disease Within the next decade, anal cancer may emerge as a preventable form of cancer.

UR - http://www.scopus.com/inward/record.url?scp=68449083814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68449083814&partnerID=8YFLogxK

U2 - 10.2174/157339409788166751

DO - 10.2174/157339409788166751

M3 - Article

VL - 5

SP - 142

EP - 150

JO - Current Cancer Therapy Reviews

JF - Current Cancer Therapy Reviews

SN - 1573-3947

IS - 2

ER -